S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Get Rid of Your Siri Remote Once and for All This Year
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
No OPEC+ oil shakeup as Russian price cap stirs uncertainty
OPEC doesn't change its targets for oil production amid uncertainty over new Western price cap on Russian oil
Market Wizard who made $95 million for his clients in 2008 – and predicted the 2022 collapse (Ad)
As Musk is learning, content moderation is a messy job
Reformers take 6 of 14 UAW board seats, could win majority
The 3-Stock Retirement Blueprint (Ad)
FDA change ushers in cheaper, easier-to-get hearing aids
OPEC keeps oil targets amid uncertainty on Russian sanctions

DexCom - DXCM Stock Forecast, Price & News

$118.11
+0.08 (+0.07%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
$115.31
$118.51
50-Day Range
$79.64
$120.87
52-Week Range
$66.89
$144.96
Volume
1.88 million shs
Average Volume
2.40 million shs
Market Capitalization
$45.62 billion
P/E Ratio
217.72
Dividend Yield
N/A
Price Target
$120.24

DexCom MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.85 Rating Score
Upside/​Downside
1.8% Upside
$120.24 Price Target
Short Interest
Bearish
3.26% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.76
Upright™ Environmental Score
News Sentiment
0.43mentions of DexCom in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$270,288 Sold Last Quarter
Proj. Earnings Growth
36.71%
From $0.79 to $1.08 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

432nd out of 1,034 stocks

Surgical & Medical Instruments Industry

49th out of 104 stocks

DXCM stock logo

About DexCom (NASDAQ:DXCM) Stock

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Stock News Headlines

S&P 500 Component DexCom Set For Further Price, Earnings Growth (DXCM)
Glucose monitor maker DexCom surged 19% after its Q3 report, and shares are holding those gains. Wall Street sees more growth ahead in 2023.
Brokerages Set DexCom, Inc. (NASDAQ:DXCM) Target Price at $120.24
Is This Stock-Split Stock a Buy For 2023?
3 Stocks to Buy for Long-Term Growth Upside
2 Reasons to Buy DexCom, and 1 Reason to Sell
2 Growth Stocks That Are Soaring: Are They Buys?
Is It Too Late to Buy DexCom Stock?
Is DexCom a Good Healthcare Stock to Buy Now?
DexCom Stock: Bull vs. Bear
Why DexCom Stock Is Soaring Today
Dexcom Stock Soars on Earnings and Revenue Beat
DexCom (DXCM) Q3 2022 Earnings Call Transcript
Why DexCom Stock Is Rising After Hours
Should You Buy Dexcom (DXCM) Ahead of Earnings?
See More Headlines
Receive DXCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DexCom and its competitors with MarketBeat's FREE daily newsletter.

DXCM Company Calendar

Last Earnings
10/28/2021
Today
12/04/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/09/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:DXCM
CUSIP
25213110
Employees
7,000
Year Founded
1999

Price Target and Rating

Average Stock Price Forecast
$120.24
High Stock Price Forecast
$145.00
Low Stock Price Forecast
$103.00
Forecasted Upside/Downside
+1.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.85
Research Coverage
13 Analysts

Profitability

Net Income
$154.70 million
Pretax Margin
6.48%

Debt

Sales & Book Value

Annual Sales
$2.45 billion
Cash Flow
$0.95 per share
Book Value
$4.72 per share

Miscellaneous

Free Float
384,674,000
Market Cap
$45.62 billion
Optionable
Optionable
Beta
1.14

Social Links


Key Executives

  • Mr. Kevin Ronald Sayer (Age 64)
    Exec. Chairman, CEO & Pres
    Comp: $2.39M
  • Mr. Jereme M. SylvainMr. Jereme M. Sylvain (Age 42)
    Exec. VP, CFO & Chief Accounting Officer
    Comp: $783.16k
  • Mr. Jacob Steven LeachMr. Jacob Steven Leach (Age 44)
    Exec. VP & COO
    Comp: $915.93k
  • Mr. Paul R. FlynnMr. Paul R. Flynn (Age 53)
    Exec. VP of Global Revenue
    Comp: $761.52k
  • Mr. Shelly Ramasamy Selvaraj (Age 63)
    Sr. VP & Chief Information Officer
  • Mr. Sean Christensen
    Director of Corp. Affairs & Head of Investor Relations
  • Mr. Michael Brown (Age 52)
    Exec. VP & Chief Legal Officer
  • Mr. Matthew Dolan (Age 41)
    Exec. VP of Strategy, Corp. Devel. & Dexcom Labs
  • Ms. Sadie M. SternMs. Sadie M. Stern (Age 47)
    Exec. VP & Chief HR Officer
  • Mr. Andrew K. BaloMr. Andrew K. Balo (Age 74)
    Exec. VP of Global Medical Affairs, Access & Evidence













DXCM Stock - Frequently Asked Questions

Should I buy or sell DexCom stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DXCM shares.
View DXCM analyst ratings
or view top-rated stocks.

What is DexCom's stock price forecast for 2023?

13 brokerages have issued twelve-month target prices for DexCom's shares. Their DXCM share price forecasts range from $103.00 to $145.00. On average, they predict the company's stock price to reach $120.24 in the next year. This suggests a possible upside of 1.8% from the stock's current price.
View analysts price targets for DXCM
or view top-rated stocks among Wall Street analysts.

How have DXCM shares performed in 2022?

DexCom's stock was trading at $134.2375 at the start of the year. Since then, DXCM shares have decreased by 12.0% and is now trading at $118.11.
View the best growth stocks for 2022 here
.

Are investors shorting DexCom?

DexCom saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 12,590,000 shares, an increase of 5.8% from the October 31st total of 11,900,000 shares. Based on an average daily trading volume, of 2,770,000 shares, the short-interest ratio is currently 4.5 days.
View DexCom's Short Interest
.

When is DexCom's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 9th 2023.
View our DXCM earnings forecast
.

How were DexCom's earnings last quarter?

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Thursday, October, 28th. The medical device company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.16 by $0.07. The medical device company had revenue of $650.20 million for the quarter, compared to the consensus estimate of $617.07 million. DexCom had a trailing twelve-month return on equity of 13.27% and a net margin of 8.24%. The business's quarterly revenue was up 29.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.24 EPS.
Read the conference call transcript
.

When did DexCom's stock split?

DexCom shares split on Friday, June 10th 2022. The 4-1 split was announced on Friday, March 25th 2022. The newly issued shares were payable to shareholders after the market closes on Thursday, June 9th 2022. An investor that had 100 shares of stock prior to the split would have 400 shares after the split.

What guidance has DexCom issued on next quarter's earnings?

DexCom issued an update on its FY 2022 earnings guidance on Thursday, November, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.88 billion-$2.91 billion, compared to the consensus revenue estimate of $2.89 billion.

What is Kevin Sayer's approval rating as DexCom's CEO?

347 employees have rated DexCom Chief Executive Officer Kevin Sayer on Glassdoor.com. Kevin Sayer has an approval rating of 88% among the company's employees.

What other stocks do shareholders of DexCom own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), PayPal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Tesla (TSLA), Salesforce (CRM), ServiceNow (NOW), Walt Disney (DIS), Trade Desk (TTD) and Shopify (SHOP).

What is DexCom's stock symbol?

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Who are DexCom's major shareholders?

DexCom's stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (11.31%), Baillie Gifford & Co. (4.61%), Sands Capital Management LLC (4.32%), Jennison Associates LLC (1.80%), Blair William & Co. IL (1.20%) and Price T Rowe Associates Inc. MD (1.03%). Insiders that own company stock include Andrew K Balo, Andrew K Balo, Barbara Kahn, Barry J Regan, Bridgette P Heller, Chad Patterson, Donald Abbey, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jereme M Sylvain, Jereme M Sylvain, Kevin R Sayer, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Paul R Flynn, Quentin S Blackford, Richard Alexander Collins, Richard Doubleday, Sadie Stern, Shelly Ramasamy Selvaraj, Steven R Altman, Steven Robert Pacelli and Sumi Shrishrimal.
View institutional ownership trends
.

How do I buy shares of DexCom?

Shares of DXCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DexCom's stock price today?

One share of DXCM stock can currently be purchased for approximately $118.11.

How much money does DexCom make?

DexCom (NASDAQ:DXCM) has a market capitalization of $45.62 billion and generates $2.45 billion in revenue each year. The medical device company earns $154.70 million in net income (profit) each year or $0.5425 on an earnings per share basis.

How many employees does DexCom have?

The company employs 7,000 workers across the globe.

Does DexCom have any subsidiaries?
The following companies are subsidiares of DexCom: DexCapital LLC, DexCom (Canada) Inc., DexCom (UK) Distribution Ltd., DexCom (UK) Intermediate Holdings Ltd., DexCom (UK) Ltd., DexCom Asia Pacific Operations PTE Ltd., DexCom Canada Co, DexCom Deutschland GmbH, DexCom International Ltd., DexCom Kommanditbolag, DexCom Operating Ltd., DexCom Philippines Inc, DexCom Suisse GmbH, Nintamed Handels GmbH, SweetSpot Diabetes Care Inc, The Glucose Program LLC, and TypeZero Technologies Inc.
Read More
How can I contact DexCom?

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.dexcom.com. The medical device company can be reached via phone at (858) 200-0200, via email at investorrelations@dexcom.com, or via fax at 858-200-0201.

This page (NASDAQ:DXCM) was last updated on 12/4/2022 by MarketBeat.com Staff